Journal Watch · Nature Communications · 2026

microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3.

These findings identify miR-25-mediated SDC3 repression as a driver of immune resistance and suggest strategies to convert immune-cold tumors into ICT-responsive hot tumors, offering avenues to enhance ICT.

Zhu Z, Han W, Deng Y et al.Nature Communications3 min readPharma relevance 60/100

DOI: 10.1038/s41467-026-73339-yPMID: 42161938Study type: preclinical (animal / model) study

TL;DR

These findings identify miR-25-mediated SDC3 repression as a driver of immune resistance and suggest strategies to convert immune-cold tumors into ICT-responsive hot tumors, offering avenues to enhance ICT.

Key findings

  • Editing the miR-25 binding site in Sdc3 restores SDC3 expression and overcomes resistance.
  • These findings identify miR-25-mediated SDC3 repression as a driver of immune resistance and suggest strategies to convert immune-cold tumors into ICT-responsive hot tumors, offering avenues to enhance ICT.

What they did

Single-cell transcriptomics reveals that miR-25 deficiency activates innate and humoral immunity by increasing major histocompatibility complex class II (MHC II) expression in tumor-associated macrophages (TAMs) and enhancing classical complement signaling in cancer-associated fibroblasts (CAFs). Complement activation shifts CAFs toward an inflammatory (iCAF) state, reduces suppressive crosstalk with TAMs, and promotes a pro-inflammatory TME. Mechanistically, miR-25 represses Syndecan-3 (SDC3) in response to interferon-γ (IFN-γ).

Full abstract (original)

Background: Immune checkpoint therapy (ICT) can induce durable tumor control but is limited by primary and acquired resistance. The mechanisms underlying immune-resistant tumor microenvironments (TMEs) remain incompletely understood. Here we show that deletion of microRNA-25 (miR-25) sensitizes tumors to ICT across multiple syngeneic mouse models.

What they did: Single-cell transcriptomics reveals that miR-25 deficiency activates innate and humoral immunity by increasing major histocompatibility complex class II (MHC II) expression in tumor-associated macrophages (TAMs) and enhancing classical complement signaling in cancer-associated fibroblasts (CAFs). Complement activation shifts CAFs toward an inflammatory (iCAF) state, reduces suppressive crosstalk with TAMs, and promotes a pro-inflammatory TME. Mechanistically, miR-25 represses Syndecan-3 (SDC3) in response to interferon-γ (IFN-γ).

Results & conclusions: Editing the miR-25 binding site in Sdc3 restores SDC3 expression and overcomes resistance. These findings identify miR-25-mediated SDC3 repression as a driver of immune resistance and suggest strategies to convert immune-cold tumors into ICT-responsive hot tumors, offering avenues to enhance ICT.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-73339-y · PubMed 42161938.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

These findings identify miR-25-mediated SDC3 repression as a driver of immune resistance and suggest strategies to convert immune-cold tumors into ICT-responsive hot tumors, offering avenues to enhance ICT.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. Single-cell transcriptomics reveals that miR-25 deficiency activates innate and humoral immunity by increasing major histocompatibility complex class II (MHC II) expression in tumor-associated macrophages (TAMs) and enhancing classical complement signaling in cancer-associated fibroblasts (CAFs).

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-73339-y. PubMed ID: 42161938. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhu Z, Han W, Deng Y et al.. microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3.. Nature Communications (2026). DOI: 10.1038/s41467-026-73339-y.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/microrna-25-drives-immune-checkpoint-therapy-resistance-by-repressing-in-73339y/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides